Consensus Arrowhead Pharmaceuticals, Inc.

Equities

ARWR

US04280A1007

Market Closed - Nasdaq Other stock markets 21:00:00 13/09/2024 BST			5-day change	1st Jan Change
21.49 ^USD	+6.20%		-3.29%	-29.77%

09-10	Arrowhead Pharmaceuticals' Plozasiran Receives FDA Breakthrough Therapy Designation	MT
09-10	Arrowhead Pharmaceuticals Gets FDA Breakthrough Designation for Plozasiran	DJ

Evolution of the Average Target: Arrowhead Pharmaceuticals, Inc.

Evolution of the Target Price: Arrowhead Pharmaceuticals, Inc.

Changes in Analyst Recommendations: Arrowhead Pharmaceuticals, Inc.

7d941205def87cecbe1.MqUf9ehmGcH-Zg-rmPtVA9xy38i3_w7Eup9xzAVN9V8.WuRLpac5SfCyPH3BrZo_NpE06P7CzWuwwswW4TMcuxBby0zHpBYoh5QcZA~c682567b0c0bfc27cf5c0868657f713b

Analysts' recommendations: Arrowhead Pharmaceuticals, Inc.

Analyst recommendations: Estee Lauder, Sentinelone, Snowflake, Wolfspeed, Admiral...	08-22
Analyst recommendations: Epam Systems, Five9, T-Mobile, Lyft, Under Armour...	08-09
Analyst recommendations: CrowdStrike, Johnson & Johnson, Netflix, Nvidia, Snap...	07-23
HC Wainwright Cuts Price Target on Arrowhead Pharmaceuticals to $60 From $90, Keeps Buy Rating	07-05	MT
UBS Cuts Price Target on Arrowhead Pharmaceuticals to $71 From $75, Keeps Buy Rating	05-10	MT
B. Riley Adjusts Arrowhead Pharmaceuticals' PT to $55 From $50, Keeps Buy Rating	02-08	MT
UBS Adjusts Price Target on Arrowhead Pharmaceuticals to $75 From $78, Maintains Buy Rating	02-07	MT
BofA Securities Initiates Arrowhead Pharmaceuticals at Buy Rating With $29 Price Target	12-04	MT
B. Riley Lowers Arrowhead Pharmaceuticals' Price Target to $50 From $60, Notes Higher Cash Burn; Keeps Buy Rating	12-04	MT
Morgan Stanley Cuts Price Target on Arrowhead Pharmaceuticals to $37 From $40, Maintains Equal-Weight Rating	11-30	MT
TD Cowen Starts Arrowhead Pharmaceuticals at Outperform	21/07/23	MT
Piper Sandler Adjusts Price Target on Arrowhead Pharmaceuticals to $59 From $52, Maintains Overweight Rating	02/06/23	MT
SVB Leerink Downgrades Arrowhead Pharmaceuticals to Market Perform From Outperform, Price Target is $40	12/05/23	MT
Goldman Sachs Adjusts Arrowhead Pharmaceuticals' Price Target to $73 From $65, Keeps Buy Rating	03/05/23	MT
Morgan Stanley Raises Price Target on Arrowhead Pharmaceuticals to $40 From $37, Maintains Equalweight Rating	03/05/23	MT
SVB Securities Upgrades Arrowhead Pharmaceuticals to Outperform From Market Perform, Raises PT to $35 From $21	12/04/23	MT
RBC Capital Adjusts Arrowhead Pharmaceuticals Price Target to $60 From $77, Maintains Outperform - Speculative Risk Rating	06/04/23	MT
Bernstein Initiates Arrowhead Pharmaceuticals at Market Perform With $27 Price Target	21/03/23	MT
B. Riley Lowers Arrowhead Pharmaceuticals' Price Target to $55 From $59, Keeps Buy Rating	08/02/23	MT
UBS Adjusts Arrowhead Pharmaceuticals' Price Target to $78 From $80, Maintains Buy Rating	07/02/23	MT
Baird Trims Price Target on Arrowhead Pharmaceuticals to $58 From $60, Maintains Outperform Rating	07/02/23	MT
RBC Capital Adjusts Price Target on Arrowhead Pharmaceuticals to $77 From $83 on Hepatitis B Virus Therapy Deprioritization, Keeps Outperform Rating	07/02/23	MT
Piper Sandler Adjusts Arrowhead Pharmaceuticals' Price Target to $52 From $55, Maintains Overweight Rating	07/02/23	MT
UBS Adjusts Arrowhead Pharmaceuticals Price Target to $80 From $88, Maintains Buy Rating	10/01/23	MT
Chardan Adjusts Price Target on Arrowhead Pharmaceuticals to $60 From $82, Keeps Buy Rating	10/01/23	MT

More recommendations

Sector Comparison:

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Analyst Opinion	4m Revision of opinion	Divergence of analysts' opinions	Divergence of Target Price	Ecart obj. / dr
	ARROWHEAD PHARMACEUTICALS, INC.					+120.04%
	REGENERON PHARMACEUTICALS, INC.					+0.77%
	VERTEX PHARMACEUTICALS INCORPORATED					+5.04%
	ARGENX SE					+4.66%
	BIONTECH SE					-10.73%
	BEIGENE, LTD.					+37.52%
	SUMMIT THERAPEUTICS INC.					-23.10%
	GENMAB A/S					+33.89%
	WUXI APPTEC CO., LTD.					+47.62%
	VAXCYTE, INC.					+25.00%
	Average					+24.07%
	Weighted average by Cap.					+6.99%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

21.49USD

Average target price

47.29USD

Spread / Average Target

+120.04%

High Price Target

71.00USD

Spread / Highest target

+230.39%

Low Price Target

20.00USD

Spread / Lowest Target

-6.93%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

UBS
B. Riley
BofA Securities
Morgan Stanley
TD Cowen
Piper Sandler
SVB Securities LLC
Goldman Sachs
RBC Capital Markets
Bernstein
Baird
Chardan Research
HC Wainwright
Jefferies & Co.
SVB Leerink
Chardan